Annual report
6951.TEDINET S100R6SW
Period2022-04-01 → 2023-03-31
Filed2023-06-28
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Amended by S100RS6V (2023-08-30).
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥162.7bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥138.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥110.4bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥117.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥111.3bn | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥24.2bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | ¥14.1bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | ¥23.5bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥16.3bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥6.5bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥7.2bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥7.4bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥23.7bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥16.7bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥17.8bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥12.3bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.7bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥5.4bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥5.9bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥17.8bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | ¥12.3bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥199.3bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥189.6bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥146.4bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥136.8bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥122.7bn | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥97.4bn | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥103.7bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥101.9bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥85.9bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥51.0bn | at 2021-03-31d | Cons. | Net assets |
| Net assets / equity | ¥45.1bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥41.6bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥34.3bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥44.2bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥32.0bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥42.4bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥14.5bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥14.0bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥9.3bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥3.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥22.6bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥3.4bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥3.7bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥4.8bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥5.7bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥648m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥7.0bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥4.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.5bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥8.7bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥5.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥3.3bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥5.4bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥3.7bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥349.34 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥246.78 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥77.51 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥110.94 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥122.95 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥1,995.55 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,684.08 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,055.5 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥933.07 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥860.9 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 51.1% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 45.3% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.8% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.0% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.9% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 19.0% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 17.9% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.8% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 12.4% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 15.0% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 3,351 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 3,291 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 3,198 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 3,165 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 3,029 | at 2019-03-31d | Cons. | Number of employees |
| Revenue | ¥135.3bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥117.7bn | 2021-04-01 → 2022-03-31 | Standalone | Net sales |
| Revenue | ¥93.1bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥102.1bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥93.9bn | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥20.9bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | ¥11.3bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥22.9bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥14.4bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥4.5bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥6.2bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥6.4bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥22.3bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥15.5bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥17.5bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥12.1bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥3.6bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥4.7bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥5.3bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥169.3bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥159.8bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥121.2bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥113.2bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥103.0bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥75.6bn | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥80.7bn | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥93.7bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥79.0bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥46.0bn | at 2021-03-31d | Standalone | Net assets |
| Net assets / equity | ¥41.9bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥38.7bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥17.6bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥27.7bn | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥343.37 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥242.8 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥74.16 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥97.13 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥108.89 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥66 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥24 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥24 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥16.5 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,836 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,548.9 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥952.79 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥867.13 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥802 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 55.4% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 49.5% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.0% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.0% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.6% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 20.3% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 19.3% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.1% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 11.6% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 14.2% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 51,532,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 51,532,000 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 48,857,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 48,857,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 48,857,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 2,259 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 2,092 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 1,950 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 1,920 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 1,907 | at 2019-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 62
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥449m |
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥381m |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | ¥45.1bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥5.4bn |
| Industrial Equipmentreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥523m |
| Industrial Equipmentreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥1.1bn |
| Industrial Equipmentreportable segment | employees | at 2023-03-31 | 564 pure |
| Industrial Equipmentreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥49.5bn |
| Industrial Equipmentreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥49.5bn |
| Industrial Equipmentreportable segment | segment assets | at 2023-03-31 | ¥44.0bn |
| Industrial Equipmentreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥23.3bn |
| Medical Equipmentreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥158m |
| Medical Equipmentreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥402m |
| Medical Equipmentreportable segment | employees | at 2023-03-31 | 301 pure |
| Medical Equipmentreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥18.4bn |
| Medical Equipmentreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥18.4bn |
| Medical Equipmentreportable segment | segment assets | at 2023-03-31 | ¥15.5bn |
| Medical Equipmentreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥530m |
| Scientific And Measurement Instrumentsreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥2.5bn |
| Scientific And Measurement Instrumentsreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥2.8bn |
| Scientific And Measurement Instrumentsreportable segment | employees | at 2023-03-31 | 2171 pure |
| Scientific And Measurement Instrumentsreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥94.8bn |
| Scientific And Measurement Instrumentsreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥94.8bn |
| Scientific And Measurement Instrumentsreportable segment | segment assets | at 2023-03-31 | ¥94.6bn |
| Scientific And Measurement Instrumentsreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥5.8bn |
| —segment total | capex | 2022-04-01 → 2023-03-31 | ¥3.2bn |
| —segment total | depreciation | 2022-04-01 → 2023-03-31 | ¥4.3bn |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥162.7bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥162.7bn |
| —segment total | segment assets | at 2023-03-31 | ¥154.1bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥29.6bn |
| Reconciling Itemsreconciling | capex | 2021-04-01 → 2022-03-31 | ¥168m |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥287m |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | ¥53.9bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥4.9bn |
| Industrial Equipmentreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥3.5bn |
| Industrial Equipmentreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥891m |
| Industrial Equipmentreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥34.0bn |
| Industrial Equipmentreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥34.0bn |
| Industrial Equipmentreportable segment | segment assets | at 2022-03-31 | ¥31.8bn |
| Industrial Equipmentreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥13.1bn |
| Medical Equipmentreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥1.0bn |
| Medical Equipmentreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥207m |
| Medical Equipmentreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥19.3bn |
| Medical Equipmentreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥19.3bn |
| Medical Equipmentreportable segment | segment assets | at 2022-03-31 | ¥16.3bn |
| Medical Equipmentreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥1.1bn |
| Scientific And Measurement Instrumentsreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥2.1bn |
| Scientific And Measurement Instrumentsreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥2.7bn |
| Scientific And Measurement Instrumentsreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥85.1bn |
| Scientific And Measurement Instrumentsreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥85.1bn |
| Scientific And Measurement Instrumentsreportable segment | segment assets | at 2022-03-31 | ¥87.6bn |
| Scientific And Measurement Instrumentsreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥4.8bn |
| —segment total | capex | 2021-04-01 → 2022-03-31 | ¥6.7bn |
| —segment total | depreciation | 2021-04-01 → 2022-03-31 | ¥3.8bn |
| —segment total | revenue | 2021-04-01 → 2022-03-31 | ¥138.4bn |
| —segment total | revenue external | 2021-04-01 → 2022-03-31 | ¥138.4bn |
| —segment total | segment assets | at 2022-03-31 | ¥135.6bn |
| —segment total | segment profit | 2021-04-01 → 2022-03-31 | ¥19.0bn |
| Industrial Equipmentreportable segment | employees | at 2023-03-31 | 400 pure |
| Medical Equipmentreportable segment | employees | at 2023-03-31 | 282 pure |
| Scientific And Measurement Instrumentsreportable segment | employees | at 2023-03-31 | 1417 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,845
| Item | Context | Value | Unit |
|---|---|---|---|
| Total return on share price index | Prior3YearInstant_NonConsolidatedMember | 0.859 | |
| Total return on share price index | Prior2YearInstant_NonConsolidatedMember | 1.221 | |
| Total return on share price index | Prior1YearInstant_NonConsolidatedMember | 1.246 | |
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | 1.318 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E01905-000ScientificAndMeasurementInstrumentsReportableSegmentsMember | 2171 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E01905-000IndustrialEquipmentReportableSegmentsMember | 564 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E01905-000MedicalEquipmentReportableSegmentsMember | 301 | |
| Number of employees | CurrentYearInstant_CorporateSharedMember | 315 | |
| Number of employees | CurrentYearInstant | 3351 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 2259 | |
| Average age years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 44.6 | |
| Average length of service years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 16.9 | |
| Average annual salary information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 7892000 | JPY |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E01905-000ScientificAndMeasurementInstrumentsReportableSegmentsMember | 1417 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E01905-000IndustrialEquipmentReportableSegmentsMember | 400 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E01905-000MedicalEquipmentReportableSegmentsMember | 282 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 160 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 2259 | |
| Research and development expenses research and development activities | CurrentYearDuration | 10391000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E01905-000ScientificAndMeasurementInstrumentsReportableSegmentsMember | 6920000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E01905-000IndustrialEquipmentReportableSegmentsMember | 1781000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E01905-000MedicalEquipmentReportableSegmentsMember | 1688000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 3665000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E01905-000ScientificAndMeasurementInstrumentsReportableSegmentsMember | 2533000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E01905-000IndustrialEquipmentReportableSegmentsMember | 523000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E01905-000MedicalEquipmentReportableSegmentsMember | 158000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 51532800 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 51532800 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 51532800 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 51532800 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 43 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 59 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 301 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 288 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 31 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 18350 | |
| Number of shareholders total | CurrentYearInstant_OrdinaryShareMember | 19072 | |
| Number of shares held number of units national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shares held number of units financial institutions | CurrentYearInstant_OrdinaryShareMember | 158929 | |
| Number of shares held number of units financial service providers | CurrentYearInstant_OrdinaryShareMember | 15734 | |
| Number of shares held number of units other corporations | CurrentYearInstant_OrdinaryShareMember | 51228 | |
| Number of shares held number of units foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 172424 | |
| Number of shares held number of units foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 116 | |
| Number of shares held number of units individuals and others | CurrentYearInstant_OrdinaryShareMember | 116548 | |
| Number of shares held number of units total | CurrentYearInstant_OrdinaryShareMember | 514979 | |
| Number of shares held shares less than one unit | CurrentYearInstant_OrdinaryShareMember | 34900 | |
| Percentage of shareholdings national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Percentage of shareholdings financial institutions | CurrentYearInstant_OrdinaryShareMember | 0.3086 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |